Navigation Links
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
Date:2/7/2013

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends.

"We were able to demonstrate that this applied across all patients and that those who had the greatest benefit from the drug while it was administered retained this benefit," says senior author Dr. Tito Fojo, of the National Cancer Institute at the National Institutes of Health.

Sunitinib, which is approved around the world for the treatment of several different cancers, works by targeting proteins on the blood vessels that feed tumors. Animal studies have suggested that treatment with sunitinib may induce changes in tumor vessels or adaptations within tumors themselves that could promote cancer growth and spread.

When Dr. Fojo and his colleagues analyzed more than 10,000 data points from the pivotal randomized phase 3 clinical trial that led to sunitinib's approval, the evidence clearly showed that no matter how long patients took sunitinib, it was not harmful, did not accelerate tumor growth, and did not shorten survival after treatment ended. During treatment, the drug slowed tumor growth and prolonged the patients' survival.

"Last year, I was approached by two patients who had grave concerns about taking sunitinib due to an article conducted in animals. I realized that if clinical data exist that refute basic science, they must be published," recalls Dr. Fojo.

The researchers' findings indicate that sunitinib can benefit patients without altering tumor biology after the drug is stopped. "We hope this can be generalized to similar drugs but recognize that further studies will be needed," says first author Dr. Krastan Blagoev of the National Science Foundation. "Nevertheless, other drugs also approved worldwide for a variety of cancersincluding sorafenib, pazopanib, and axitinibare similar to sunitinib, and this will give some reassurances that one need not expect things to get worse after such drugs are discontinued."


'/>"/>

Contact: Mary Beth OLeary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert  

Related medicine news :

1. Potential new technique for anticancer radiotherapy could provide alternative to brachytherapy
2. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
3. Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
4. Fat Loss 4 Idiots: Review Examining New "Accelerated Fat Loss Diet" Released By DietsAndFitnessGuides.com
5. EzW2 Software From Halfpricesoft.com Updated To Accelerate Tax Reporting For Startups
6. Studying marrow, URMC researchers accelerate blood stem cells
7. Topical simvastatin shown to accelerate wound healing in diabetes
8. Concussions and head impacts may accelerate brain aging
9. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
10. Higher energies for laser-accelerated particles possible
11. Accelerated radiation treatment effective for noninvasive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends
(Date:3/1/2017)... Calif. (PRWEB) , ... March 01, 2017 , ... Award-winning ... has completed 25 medical mission trips in underdeveloped nations, averaging more than one trip ... 2016. An article on the website features the details of his charitable ...
(Date:3/1/2017)... ... March 01, 2017 , ... NYC based Integrated practice Living Well ... to announce the addition of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. ... Cornell University with a Bachelor of Science degree in biology. He then obtained his ...
(Date:3/1/2017)... ... 01, 2017 , ... “There is Comfort for the Soul”: a loving account ... their all-too-brief time together, and the soul-healing comfort provided by God’s presence in the ... published author, Jerie A. Tau, a dog-loving medical professional whose work takes her to ...
(Date:3/1/2017)... ... ... Way: Key To One Flesh”: a collection of real marital scenarios and solutions for ... Cecilia Chiam, a writer who emigrated to the United States in 1978. , ... problems with the guidance and support of Holy Scripture. , “This is a ...
(Date:3/1/2017)... ... March 01, 2017 , ... Adherence Compliance, the ... Cannabis Compliance Program for Regulatory Agencies. The regulatory agency program is the first ... internal or outsourced compliance program options, as well as an app for inspections ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Mar 01, 2017 ... Research and Markets has announced ... to 2017" report to their offering. The ... report provides understanding and access to partnering deals and agreements entered ... provides an analysis of partnering deals. The majority of deals are ...
(Date:3/1/2017)... Research and Markets has announced the addition of the ... to their offering. ... This analysis is one of the most accurate studies performed ... financial data derived from varied research sources to present unique and ... market during the next five years, including a deep dive analysis ...
(Date:3/1/2017)... , March 1, 2017  Numotion, the nation,s leading ... availability of Tek RMD ("robotic mobilization device") by Matia ... Tek RMD is a motorized standing movement device that ... manual wheelchair to complete everyday activities from a standing ... a Tek RMD unassisted. Numotion is the exclusive distributor ...
Breaking Medicine Technology: